ATA-188 is under clinical development by Atara Biotherapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ATA-188’s likelihood of approval (LoA) and phase transition for Primary Progressive Multiple Sclerosis (PPMS) took place on 07 Mar 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 07 Mar 2022 increased ATA-188’s LoA and PTSR for Secondary Progressive Multiple Sclerosis (SPMS).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ATA-188 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ATA-188 overview

ATA-188 is under development for the treatment of progressive forms of multiple sclerosis such as progressive relapsing multiple sclerosis and relapsing-remitting multiple sclerosis. It is administered as an intravenous infusion. The drug candidate comprises of Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTL). EBV-CTL utilizes a technology in which T-cells are collected from the blood of third-party donors (allogenic) and then exposed to EBV antigens. The resulted activated T-cells are used for the therapeutic activity in the patients. It was also under development for the treatment of Epstein Barr virus infection caused gastric cancer.

Atara Biotherapeutics overview

Atara Biotherapeutics (Atara) is a biopharmaceutical company specialized in T-cell immunotherapy. The company uses its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. It is evaluating its lead candidate, tabelecleucel in Phase III clinical trials for the treatment of epstein-barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) following hematopoietic cell transplant and solid organ transplant in patients who refracted rituximab. Its pipeline product candidates that are being developed for multiple indications in various stages of clinical trials include ATA188, ATA2271, ATA3219, ATA3271 and other CAR T programs. Atara is headquartered in South San Francisco, California, the US.

Quick View ATA-188 LOA Data

Report Segments
  • Innovator
Drug Name
  • ATA-188
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Central Nervous System
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.